The Pulse
Isomorphic Labs Opens Funding Talks at a $40 Billion Valuation
Isomorphic Labs is in early talks to raise new funding at a valuation of at least $40 billion, with one estimate reaching $50 billion. The Alphabet-backed drug-discovery company raised $2.1 billion in a Series B round in May, but the new fi
AI.info Team · Written with AI ·
A $40 billion floor, with terms unsettled
Isomorphic Labs is in early talks to raise new funding at a valuation of at least $40 billion, according to a Bloomberg report published October 8. One person familiar with the effort said the round could value the company as high as $50 billion. The financing has not closed, and the terms could change.
The figures describe a potential valuation, not the amount the company is seeking to raise. Bloomberg said Isomorphic Labs did not respond to a request for comment. With negotiations at an early stage, neither the final valuation nor the structure of a deal is established.
Five months after a $2.1 billion round
The talks follow a $2.1 billion Series B that Isomorphic Labs announced on May 12. The company said Thrive Capital led the round, with participation from existing backers Alphabet and GV and new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The company did not disclose a valuation for that financing in its announcement.
In May, founder and chief executive Sir Demis Hassabis said, “Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential.” The statement accompanied the Series B announcement; it was not a comment on the funding discussions now underway.
The company is financing drug-design ambitions
Isomorphic Labs develops AI tools for drug design and development. In its May release, the company said it planned to use the Series B proceeds to develop and deploy its AI drug design engine, known as IsoDDE, and expand its pipeline of therapeutic programs toward the clinic. The company also described hiring across AI, engineering, drug design and clinical roles as a use for that capital.
The scale of the reported valuation reflects investor interest in a company pursuing drug discovery, but the funding talks alone do not establish that its technology has produced a medicine or cleared clinical testing. Bloomberg’s account supplies no new details about the prospective investors, the amount sought or the use of proceeds in a new round.
A proposed valuation, not a completed deal
For now, the main contrast is between a completed $2.1 billion financing in May and a potential new valuation above $40 billion only five months later. Because Isomorphic Labs did not disclose the earlier round’s valuation, the public information does not provide a confirmed basis for calculating how much its value may have risen.
The next concrete milestone is whether the early talks become a completed financing and what terms the company and investors agree to. Until then, the $40 billion figure is a reported threshold under discussion, not a final price set by a closed round.